



Oramed Pharmaceuticals Inc.
1185 Avenue of the Americas
New York, NY 10036
Phone: 1 844 9 ORAMED
www.oramed.com

COMPANY OVERVIEW

- Breakthrough platform technology for oral delivery of drugs and vaccines presently available only via injection
- Pipeline currently focused on diabetes, with potential for a variety of additional treatment indications addressing multi-billion-dollar markets
- Positive results from oral insulin (ORMD-0801) pivotal Phase 2b study
- Phase 3 studies under US FDA underway
- Oramed’s lead product, oral insulin, has potential to be the first commercial oral insulin
- Robust worldwide patent portfolio

EQUITY OVERVIEW

(as of 31/Dec/20)

Nasdaq/TASE: ORMP

Price: ~\$4.24

Market Cap: \$100 M

52 Week Range: \$2.4-\$5.88

Avg. Daily Volume (90 day): 446K

Shares Outstanding: 23.6 M

Cash/Investments: \$43.8 M (as of 8/31/20)

ANALYST COVERAGE

- H.C. Wainwright & Co.
- Ladenburg Thalmann
- Aegis Capital
- Zacks
- AGP

BETTER WAY TO TREAT DIABETES

**1 in 11 adults
on the planet has
diabetes**

1 healthcare
in 8
Is spent on diabetes



INVESTMENT HIGHLIGHTS

Breakthrough Platform Technology Delivers Injectable Drugs Orally

Oramed’s unique Protein Oral Delivery (POD™) technology enables small proteins such as insulin to travel through the gastrointestinal tract and into the bloodstream. This method is more natural and should eliminate many of the negative side-effects of injection delivery. The oral administration of current injection-only therapies for conditions including diabetes should offer clear benefits including increased compliance and safety, fewer side effects and greater comfort for patients.

Addressing \$70 Billion Market with Oral Formulations

Roughly \$70 billion worth of drugs and vaccines are currently delivered via injection. This includes the diabetes market where \$24 billion of insulin and \$6 billion of GLP-1 analogs were sold globally in 2017. The vaccine market size was approximately \$33.6 billion in 2017 and is expected to surpass \$103.6 billion by 2028.

Oral Treatment has the Potential to Curb Progression of Type 2 Diabetes

ORMD-0801 has the potential to create a new paradigm in the treatment of type 2 diabetes by orally delivering insulin at an earlier stage of treatment. Earlier treatment can potentially slow disease progression and delay late-stage complications. Oramed successfully completed a 90-day HbA1c study of ORMD-0801, which met its primary endpoint achieving a statistically significant reduction of HbA1c. Oramed is initiating Phase 3 studies under the FDA, and is pursuing a Biologics License Application (BLA) regulatory pathway for ORMD-0801 which would grant a full 12 years of marketing exclusivity, if approved.

Oral GLP-1 Analog to Stimulate Insulin Production in Type 2 Diabetes

Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone that stimulates the secretion of insulin from the pancreas. It is beneficial to type 2 diabetic patients by promoting weight loss and decreasing blood glucose. Oramed’s ORMD-0901, an oral GLP-1 analog completed small clinical trials with encouraging results it is currently in the midst of a bioavailability study in the US.

2021 ANTICIPATED UPCOMING MILESTONES

ORMD-0801: Oral Insulin	➤ Phase 3 in diabetes patients ➤ NASH trial
ORMD-0901: Oral GLP-1	➤ Bioavailability study in diabetes patients
Oral Leptin	➤ Exploratory trial